315 related articles for article (PubMed ID: 30199148)
21. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
Xu L; Lei J; Wang QZ; Li J; Wu L
Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
[TBL] [Abstract][Full Text] [Related]
23. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
24. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
[TBL] [Abstract][Full Text] [Related]
25. Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas.
Matsubara D; Yoshimoto T; Soda M; Amano Y; Kihara A; Funaki T; Ito T; Sakuma Y; Shibano T; Endo S; Hagiwara K; Ishikawa S; Fukayama M; Murakami Y; Mano H; Niki T
Cancer Sci; 2020 Jun; 111(6):2183-2195. PubMed ID: 32237253
[TBL] [Abstract][Full Text] [Related]
26. The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
Oktay E; Oflazoglu U; Varol Y; Tanriverdi O; Mermur N; Arda HU; Demir L; Keskin O; Ahmadli T; Somali I; Oztop I; Meydan N
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1201-S1208. PubMed ID: 30539871
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Thyroid Transcription Factor-1 Expression in Patients with Advanced Lung Adenocarcinoma.
Zablockis R; Žurauskas E; Danila E; Gruslys V
In Vivo; 2018; 32(6):1571-1579. PubMed ID: 30348718
[TBL] [Abstract][Full Text] [Related]
28. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
29. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
31. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
32. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1
Agaimy A; Fuchs F; Moskalev EA; Sirbu H; Hartmann A; Haller F
Virchows Arch; 2017 Nov; 471(5):599-609. PubMed ID: 28555282
[TBL] [Abstract][Full Text] [Related]
33. Frequency and types of
Lemine Sow M; El Yacoubi H; Moukafih B; Balde S; Akimana G; Najem S; El Khoyaali S; Abahssain H; Chaibi A; Zeb Khan S; Trapani D; Benzekri A; Ghaouti M; Gamra L; Mestari A; Kettani F; Rahali Y; Mrabti H; Elghissassi I; Errihani H
Tumori; 2021 Aug; 107(4):335-340. PubMed ID: 33079008
[TBL] [Abstract][Full Text] [Related]
34. Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases.
Rokutan-Kurata M; Yoshizawa A; Sumiyoshi S; Sonobe M; Menju T; Momose M; Koyama M; Shigeto S; Fujimoto M; Zhang M; Morita S; Date H; Haga H
Clin Lung Cancer; 2017 Jul; 18(4):e273-e281. PubMed ID: 28065467
[TBL] [Abstract][Full Text] [Related]
35. Distinct prognostic roles and heterogeneity of TTF1 copy number and TTF1 protein expression in non-small cell lung cancer.
Yoshimura K; Inoue Y; Mori K; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Genes Chromosomes Cancer; 2017 Jul; 56(7):570-581. PubMed ID: 28378892
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
[TBL] [Abstract][Full Text] [Related]
37. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Budczies J; Kirchner M; Kluck K; Kazdal D; Glade J; Allgäuer M; Kriegsmann M; Heußel CP; Herth FJ; Winter H; Meister M; Muley T; Goldmann T; Fröhling S; Wermke M; Waller CF; Tufman A; Reck M; Peters S; Schirmacher P; Thomas M; Christopoulos P; Stenzinger A
Cancer Immunol Immunother; 2022 Feb; 71(2):251-265. PubMed ID: 34125345
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
[TBL] [Abstract][Full Text] [Related]
39. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
[TBL] [Abstract][Full Text] [Related]
40. Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.
Yang B; Lee H; Um SW; Kim K; Zo JI; Shim YM; Jung Kwon O; Lee KS; Ahn MJ; Kim H
Lung Cancer; 2019 Mar; 129():28-34. PubMed ID: 30797488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
